In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

Data from a nationwide German registry with data from nearly 3,000 long-term survivors of radical prostatectomy sheds light on how frailty impacts the lives they lead. Treat or observe? Dr. Joseph ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...